Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Stopped Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding

Conditions

• Hidradenitis Suppurativa

Interventions

• DRUG: Deucravacitinib
• DRUG: Placebo

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

• [object Object]